Observational Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2016; 22(25): 5814-5821
Published online Jul 7, 2016. doi: 10.3748/wjg.v22.i25.5814
Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma
Song-Zhu Yang, An-Qiang Wang, Juan Du, Jian-Tao Wang, Wei-Wei Yu, Qing Liu, Yan-Fang Wu, Shu-Guang Chen
Song-Zhu Yang, Jian-Tao Wang, Wei-Wei Yu, Qing Liu, Yan-Fang Wu, Department of Hepatobiliary Surgery, Yantaishan Hospital, Yantai 264001, Shandong Province, China
An-Qiang Wang, Shu-Guang Chen, Department of Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Juan Du, Department of Health Management, The General Hospital Rocket Forces of the Chinese People’s Liberation Army, Beijing 100088, China
Author contributions: Yang SZ and Wang AQ contributed equally to this work; Yang SZ, Wang AQ, Du J and Chen SG designed the research; Yang SZ, Wang AQ, Du J, Wang JT, Yu WW, Liu Q and Wu YF performed the research; Yu WW and Liu Q contributed new reagents and analytic tools; Yang SZ, Wang JT, Wu YF and Chen SG analyzed the data; and Yang SZ, Wang AQ and Chen SG wrote the paper.
Institutional review board statement: The study was reviewed and approved by the Yantaishan Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have no conflict of interest to disclosure.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shu-Guang Chen, MD, Professor, Department of Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China. pumchcsg@163.com
Telephone: +86-10-69155200 Fax: +86-10-69155201
Received: April 5, 2016
Peer-review started: April 6, 2016
First decision: May 12, 2016
Revised: May 13, 2016
Accepted: June 2, 2016
Article in press: June 2, 2016
Published online: July 7, 2016
Processing time: 90 Days and 3.4 Hours
Abstract

AIM: To investigate the relationship between ARID1A expression and clinicopathologic parameters, as well as its prognostic value, for patients with intrahepatic cholangiocarcinoma (IHCC).

METHODS: We assessed ARID1A protein and mRNA expression in IHCC tissues and paracarcinomatous (PC) tissues from 57 patients with IHCC using western blot and quantitative real-time reverse transcription polymerase chain reaction, respectively. We used Fisher’s exact and χ2 tests to analyze relationships between clinicopathological parameters and ARID1A expression. The Kaplan-Meier method and Cox regression were used to analyze survival.

RESULTS: The mean ARID1A protein level in IHCC tissues was 1.16 ± 0.36 relative units (RU), which was significantly lower than that in PC tissues (1.26 ± 0.21 RU, P < 0.01) and NL tissues (1.11 ± 0.31, P < 0.001). The mean ARID1A mRNA level in IHCC tissues (1.20 ± 0.18) was also lower than that in PC tissues (1.27 ± 0.15, P < 0.001) and normal liver tissues (1.15 ± 0.34, P < 0.001). Low ARID1A expression was significantly associated with tumor nodules, vein invasion, and recurrence. Median overall survival (OS) and disease-free survival (DFS) for the low ARID1A expression group was 15.0 and 7.0 mo, respectively, which were significantly shorter than those for the high ARID1A expression group at 25.0 and 22.0 mo (OS: P < 0.01; DFS: P < 0.001), respectively. Low ARID1A expression was significantly associated with worse OS (HR = 3.967, 95%CI: 1.299-12.118, P = 0.016) in multivariate analyses.

CONCLUSION: Low expression of ARID1A is associated with poor prognosis in patients with IHCC, and thus may be a potential prognostic biomarker candidate in IHCC.

Keywords: ARID1A; Intrahepatic cholangiocarcinoma; Progression; Prognosis; Biomarker

Core tip: We investigated the relationship between ARID1A expression and clinicopathologic parameters, as well as its prognostic value, for patients with intrahepatic cholangiocarcinoma (IHCC). We examined ARID1A protein and mRNA expression in IHCC and paracarcinomatous (PC) tissue from 57 patients with IHCC. The mean ARID1A protein and mRNA expression levels in IHCC tissues were significantly lower than those in PC tissues and normal liver tissues. Low ARID1A expression was significantly associated with tumor nodules, vein invasion, and recurrence. Low ARID1A expression was significantly associated with worse overall survival in multivariate analyses. ARID1A may be a potential prognostic biomarker candidate in IHCC.